Jean Mah

Dr. Jean Mah

orcid

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2014 in Neuromuscular Disorders
Verified
Journal Article
Closed access
JMJean Mah
Jean Mah
LKLawrence Korngut
Lawrence Korngut
JDJonathan Dykeman
Jonathan Dykeman
LDLundy Day
Lundy Day
TPTamara Pringsheim
Tamara Pringsheim
NJNathalie Jette
Nathalie Jette

24 November 2015 in Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques
Verified
Journal Article
Closed access
PDF file
JMJean Mah
Jean Mah
LKLawrence Korngut
Lawrence Korngut
KFKirsten M. Fiest
Kirsten M. Fiest
JDJonathan Dykeman
Jonathan Dykeman
LDLundy J. Day
Lundy J. Day
NJNathalie Jette
Nathalie Jette
Background:The muscular dystrophies are a heterogeneous group of genetic muscle diseases with variable distribution of weakness and mode of inheritance.Methods:We previously performed a systematic review of worldwide population-based studies on Duchenne and Becker muscular dystrophies; the current study focused on the epidemiology of other muscular dystrophies using Medline and EMBASE databases. Two reviewers independently reviewed all abstracts, full-text articles, and abstracted data from 1985 to 2011. Pooling of prevalence estimates was performed using random-effect models.Results:A total of 1104 abstracts and 167 full-text articles were reviewed. Thirty-one studies met all eligibility criteria and were included in the final analysis. The overall pooled prevalence of combined muscular dystrophies was 16.14 (confidence interval [CI], 11.21-23.23) per 100,000. The prevalence estimates per 100,000 were 8.26 (CI, 4.99-13.68) for myotonic dystrophy, 3.95 (CI, 2.89-5.40) for facioscapulohumeral dystrophy, 1.63 (CI, 0.94-2.81) for limb girdle muscular dystrophy, and 0.99 (CI, 0.62-1.57) for congenital muscular dystrophies.Conclusions:The studies differed widely in their approaches to case ascertainment, and substantial gaps remain in the global estimates of many other types of muscular dystrophies. Additional epidemiological studies using standardized diagnostic criteria as well as multiple sources of case ascertainment will help address the economic impact and health care burden of muscular dystrophies worldwide.

1 July 2016 in Neuropsychiatric Disease and Treatment
Verified
Journal Article
Open access
PDF file
JMJean Mah
Jean Mah
Duchenne muscular dystrophy (DMD) is the most common form of muscular dystrophy in childhood. It is caused by mutations of the DMD gene, leading to progressive muscle weakness, loss of independent ambulation by early teens, and premature death due to cardiorespiratory complications. The diagnosis can usually be made after careful review of the history and examination of affected boys presenting with developmental delay, proximal weakness, and elevated serum creatine kinase, plus confirmation by muscle biopsy or genetic testing. Precise characterization of the DMD mutation is important for genetic counseling and individualized treatment. Current standard of care includes the use of corticosteroids to prolong ambulation and to delay the onset of secondary complications. Early use of cardioprotective agents, noninvasive positive pressure ventilation, and other supportive strategies has improved the life expectancy and health-related quality of life for many young adults with DMD. New emerging treatment includes viral-mediated microdystrophin gene replacement, exon skipping to restore the reading frame, and nonsense suppression therapy to allow translation and production of a modified dystrophin protein. Other potential therapeutic targets involve upregulation of compensatory proteins, reduction of the inflammatory cascade, and enhancement of muscle regeneration. So far, data from DMD clinical trials have shown limited success in delaying disease progression; unforeseen obstacles included immune response against the generated mini-dystrophin, inconsistent evidence of dystrophin production in muscle biopsies, and failure to demonstrate a significant improvement in the primary outcome measure, as defined by the 6-minute walk test in some studies. The long-term safety and efficacy of emerging treatments will depend on the selection of appropriate clinical end points and sensitive biomarkers to detect meaningful changes in disease progression. Correction of the underlying mutations using new gene-editing technologies and corticosteroid analogs with better safety profiles offers renewed hope for many individuals with DMD and their families.

1 October 2018 in Pharmacological Research
Verified
Journal Article
Open access
LCLaurie S. Conklin
Laurie S. Conklin
JDJesse M. Damsker
Jesse M. Damsker
Eric P HoffmanEric P Hoffman
Eric P Hoffman
WJWilliam J. Jusko
William J. Jusko
PMPanteleimon Mavroudis
Panteleimon Mavroudis
PCPaula R. Clemens
Paula R. Clemens
We report a first-in-patient study of vamorolone, a first-in-class dissociative steroidal anti-inflammatory drug, in Duchenne muscular dystrophy. This 2-week, open-label Phase IIa multiple ascending dose study (0.25, 0.75, 2.0, and 6.0 mg/kg/day) enrolled 48 boys with Duchenne muscular dystrophy (4 to <7 years), with outcomes including clinical safety, pharmacokinetics and pharmacodynamic biomarkers. The study design included pharmacodynamic biomarkers in three contexts of use: 1. Secondary outcomes for pharmacodynamic safety (insulin resistance, adrenal suppression, bone turnover); 2. Exploratory outcomes for drug mechanism of action; 3. Exploratory outcomes for expanded pharmacodynamic safety. Vamorolone was safe and well-tolerated through the highest dose tested (6.0 mg/kg/day) and pharmacokinetics of vamorolone were similar to prednisolone. Using pharmacodynamic biomarkers, the study demonstrated improved safety of vamorolone versus glucocorticoids as shown by reduction of insulin resistance, beneficial changes in bone turnover (loss of increased bone resorption and decreased bone formation only at the highest dose level), and a reduction in adrenal suppression. Exploratory biomarkers of pharmacodynamic efficacy showed an anti-inflammatory mechanism of action and a beneficial effect on plasma membrane stability, as demonstrated by a dose-responsive decrease in serum creatine kinase activity. With an array of pre-selected biomarkers in multiple contexts of use, we demonstrate the development of the first dissociative steroid that preserves anti-inflammatory efficacy and decreases steroid-associated safety concerns. Ongoing extension studies offer the potential to bridge exploratory efficacy biomarkers to clinical outcomes.

12 March 2024 in Neurology
Verified
Journal Article
Open access
UDUtkarsh J. Dang
Utkarsh J. Dang
JDJesse M. Damsker
Jesse M. Damsker
MGMichela Guglieri
Michela Guglieri
PCPaula R. Clemens
Paula R. Clemens
SPSeth J. Perlman
Seth J. Perlman
Eric P HoffmanEric P Hoffman
Eric P Hoffman
Background and ObjectivesVamorolone is a dissociative agonist of the glucocorticoid receptor that has shown similar efficacy and reduced safety concerns in comparison with prednisone in Duchenne muscular dystrophy (DMD). This study was conducted to ...

25 January 2022 in JAMA Network Open
Verified
Journal Article
Open access
PDF file
JMJean Mah
Jean Mah
PCPaula R. Clemens
Paula R. Clemens
MGMichela Guglieri
Michela Guglieri
ESEdward C. Smith
Edward C. Smith
RFRichard S. Finkel
Richard S. Finkel
CICINRG DNHS Investigators
CINRG DNHS Investigators
Duchenne muscular dystrophy (DMD) is a rapidly progressive X-linked recessive disease, with symptom onset before age 6 years in boys. It is the most common form of muscular dystrophy in childhood, occurring among 1 in 3600 to 9300 male newborns worldwide.1 The disease is caused by variants in the DMD gene, which codes for the dystrophin protein.2 The lack of dystrophin results in membrane fragility, necrosis, inflammation, and progressive muscle atrophy.3 Aberrant intracellular signaling cascades also contribute to DMD pathophysiology. Upregulated inflammatory gene expression and activated immune cell infiltrates, at least partially mediated by nuclear factor κ light chain enhancer of activated B cells (NF-κB) activation, are evident during early disease stages and play a significant role in disease progression.3-5 NF-κB regulates expression of numerous inflammatory genes in immune cells and muscle fibers,6-9 and the infiltration and activation of these cells can trigger muscle cell death.10,11